Oncology is the leading therapeutic area in the pharmaceutical market, representing around $273Bn and close to 20% of the total market share across all therapeutic areas, and is expected to see an increase in spending of more than $100Bn and the approval of close to 100 new oncology drugs in the next four years. However, innovative therapies are complex to administer, often with dosage and adherence issues, and have a potential dose-limiting effect. In oncology, digital therapeutics (DTx) can address these unmet needs and offer several benefits associated with patient self-management, such as increased satisfaction and trust, higher quality of life, reduced stress, and better understanding of personal responsibilities. In this article, we will review how digital therapeutics can enhance cancer patients experience with their treatment and illustrate it with concrete examples from our portfolio.